PMCB
vs
S&P 500
PMCB
S&P 500
Over the past 12 months, PMCB has underperformed S&P 500, delivering a return of -46% compared to the S&P 500's +14% growth.
Stocks Performance
PMCB vs S&P 500
Performance Gap
PMCB vs S&P 500
Performance By Year
PMCB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
PharmaCyte Biotech Inc
Glance View
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Laguna Hills, California and currently employs 4 full-time employees. The company went IPO on 2003-09-11. The firm is focused on developing cellular therapies for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Cell-in-a-Box technology is used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). The firm's lead product candidate, CypCaps is in Phase II of the clinical trials in LAPC. The company also focused on developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The firm is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant, such as cannabinoids.
